0025ee3a60
Pentagon-Agent: Vida <HEADLESS>
3.7 KiB
| type | title | author | url | date | domain | secondary_domains | format | status | priority | tags | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| source | GLP-1 Obesity Treatment Persistence Nearly Doubled from 2021 to 2024 | Blue Cross Blue Shield Health Institute / Prime Therapeutics | https://www.bcbs.com/media/pdf/BHI_Issue_Brief_GLP1_Trends.pdf | 2026-01-01 | health | report | unprocessed | high |
|
Content
BCBS Health Institute and Prime Therapeutics real-world commercial insurance data: One-year persistence rates for obesity-indicated, high-potency GLP-1 products increased from 33.2% in 2021 to 34.1% in 2022, 40.4% in 2023, and 62.6% in 2024. Semaglutide (Wegovy) specifically: 33.2% (2021) → 34.1% (2022) → 40.0% (2023) → 62.7% (2024). Adherence during first year improved from 30.2% (2021) to 55.5% (2024 H1). Drivers cited: supply shortage resolution and improved patient management.
However, long-term persistence remains poor. Prime Therapeutics year-two data: only 14% of members newly initiating a GLP-1 for obesity without diabetes were persistent at two years (1 in 7). Three-year data from earlier cohorts shows further decline to ~8-10%.
Medscape headline: "GLP-1 Persistence for Weight Loss Has Nearly Doubled."
Agent Notes
Why this matters: The previous model was based on 20-30% annual dropout rates (reflecting 2021-2022 data). Year-1 adherence has genuinely improved — nearly doubled. This is a significant update that compresses the population-level signal timeline slightly. But long-term persistence remains catastrophic, and the divergence between year-1 (62.7%) and year-2 (14%) is striking and needs explanation.
What surprised me: The magnitude of year-1 improvement (33% → 63%) in just 3 years is faster than I expected. Supply resolution explains some of it, but "improved patient management" is vague — what specifically changed? This warrants exploration.
What I expected but didn't find: Evidence that the year-1 improvement translates to year-2 or year-3 improvement. The jump from 62.7% year-1 to 14% year-2 persistence suggests the drivers of short-term adherence (supply access, initial motivation, dose titration support) are not addressing the drivers of long-term dropout.
KB connections: Relates to the GLP-1 agonist "inflationary through 2035" claim; the continuous-monitoring adherence support thesis; the OBBBA access contraction. The gap between year-1 and year-2 persistence is the specific mechanism by which the population-level mortality signal gets delayed.
Extraction hints: Two potential claims: (1) GLP-1 year-1 persistence nearly doubled 2021-2024 driven by supply normalization (factual, well-sourced); (2) GLP-1 long-term persistence (2+ years) remains 14%, representing the structural adherence ceiling under current support infrastructure.
Context: BCBS BHI is the research arm of Blue Cross Blue Shield; Prime Therapeutics is their PBM. This is commercial insurance data — excludes Medicaid, Medicare, and uninsured populations. Selection bias: commercial enrollees have better access than the populations most in need.
Curator Notes (structured handoff for extractor)
PRIMARY CONNECTION: GLP-1 agonists largest therapeutic category launch in history (inflationary through 2035) WHY ARCHIVED: Year-1 persistence improvement is the first evidence that the dropout pattern is changing — but year-2 data reveals the limitation. This creates a divergence: is adherence improving (year-1 says yes) or persistently poor (year-2/3 says yes too)? EXTRACTION HINT: Two separate claims — the year-1 improvement story and the year-2 ceiling story. Don't conflate them. The extractor should flag the commercial insurance selection bias as a scope qualification.